EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites33
Patients859

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	474
New Zealand	169
Finland	71
Switzerland	59
Saudi Arabia	43
Ireland	31
Slovenia	11
Germany	1
Total	859